Precipitation-lyophilization-homogenization (PLH) for preparation of clarithromycin nanocrystals: influencing factors on physicochemical properties and stability.

Nanocrystals is one of effective technologies used to improve solubility and dissolution behavior of poorly soluble drugs. Clarithromycin is classified in BCS class II having low bioavailability due to very low dissolution behavior. The main purpose of this study was to investigate an efficiency of clarithromycin nanocrystals preparation by precipitation-lyophilization-homogenization (PLH) combination method in comparison with high pressure homogenization (HPH) method. The factors influencing particle size reduction and physical stability were assessed. The results showed that the PLH technique provided an effective and rapid reduction of particle size of nanocrystals to 460 ± 10 nm with homogeneity size distribution after only the fifth cycle of homogenization, whereas the same size was attained after 30 cycles by the HPH method. The smallest nanocrystals were achieved by using the combination of poloxamer 407 (2%, w/v) and SLS (0.1%, w/v) as stabilizers. This combination could prevent the particle aggregation over 3-month storage at 4 °C. The results from SEM showed that the clarithromycin nanocrystals were in cubic-shaped similar to its initial particle morphology. The DSC thermogram and X-ray diffraction pattern of nanocrystals were not different from the original drug except for intensity of peaks which indicated the presenting of nanocrystals in the crystalline state and/or partial amorphous form. In addition, the dissolution of the clarithromycin nanocrystals was dramatically increased as compared to the coarse clarithromycin.

[1]  R. Müller,et al.  Preparation and characterization of quercetin nanocrystals. , 2011, Journal of pharmaceutical sciences.

[2]  Rainer H. Müller,et al.  Second generation of drug nanocrystals for delivery of poorly soluble drugs: smartCrystal technology , 2008 .

[3]  Barrett E. Rabinow,et al.  Nanosuspensions in drug delivery , 2004, Nature Reviews Drug Discovery.

[4]  E. Forssberg,et al.  Interfacial separation of particles , 2005 .

[5]  R. Müller,et al.  Buparvaquone mucoadhesive nanosuspension: preparation, optimisation and long-term stability. , 2002, International journal of pharmaceutics.

[6]  Jinming Gao,et al.  Nanonization strategies for poorly water-soluble drugs. , 2011, Drug discovery today.

[7]  R. Davé,et al.  Precipitation and stabilization of ultrafine particles of Fenofibrate in aqueous suspensions by RESOLV , 2013 .

[8]  M. Mazzotti,et al.  Miconazole nanosuspensions: Influence of formulation variables on particle size reduction and physical stability. , 2010, International journal of pharmaceutics.

[9]  Patrick Augustijns,et al.  Top-down production of drug nanocrystals: nanosuspension stabilization, miniaturization and transformation into solid products. , 2008, International journal of pharmaceutics.

[10]  Timo Laaksonen,et al.  Nanosuspensions of poorly soluble drugs: preparation and development by wet milling. , 2011, International journal of pharmaceutics.

[11]  E. Yonemochi,et al.  Physicochemical properties of amorphous clarithromycin obtained by grinding and spray drying. , 1999, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[12]  K. Amighi,et al.  Preparation and characterization of nanocrystals for solubility and dissolution rate enhancement of nifedipine. , 2005, International journal of pharmaceutics.

[13]  Rainer H Müller,et al.  State of the art of nanocrystals--special features, production, nanotoxicology aspects and intracellular delivery. , 2011, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[14]  Elaine Merisko-Liversidge,et al.  Nanosizing: a formulation approach for poorly-water-soluble compounds. , 2003, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[15]  R. Müller,et al.  Development of ascorbyl palmitate nanocrystals applying the nanosuspension technology. , 2008, International journal of pharmaceutics.

[16]  R. Kumria,et al.  Nanocrystals: Current Strategies and Trends , 2012 .

[17]  K. Mäder,et al.  Solid lipid nanoparticles: production, characterization and applications. , 2001, Advanced drug delivery reviews.

[18]  M. Gallarate,et al.  Emulsions containing partially water-miscible solvents for the preparation of drug nanosuspensions. , 2001, Journal of controlled release : official journal of the Controlled Release Society.

[19]  S. Baumgartner,et al.  Advantages of celecoxib nanosuspension formulation and transformation into tablets. , 2009, International journal of pharmaceutics.

[20]  Cornelia M Keck,et al.  Challenges and solutions for the delivery of biotech drugs--a review of drug nanocrystal technology and lipid nanoparticles. , 2004, Journal of biotechnology.

[21]  J-Y Choi,et al.  Characteristics of polymers enabling nano-comminution of water-insoluble drugs. , 2008, International journal of pharmaceutics.

[22]  Rainer H. Müller,et al.  Nanosuspensions for the formulation of poorly soluble drugs: I. Preparation by a size-reduction technique , 1998 .

[23]  R. Müller,et al.  Nanosuspensions as particulate drug formulations in therapy. Rationale for development and what we can expect for the future. , 2001, Advanced drug delivery reviews.

[24]  Takuya Kumamoto,et al.  Application of ascorbic acid 2-glucoside as a solubilizing agent for clarithromycin: solubilization and nanoparticle formation. , 2007, International journal of pharmaceutics.

[25]  A. Drake,et al.  Effect of polymer molecular weight on the production of drug nanoparticles. , 2007, Journal of pharmaceutical sciences.